Purpose Anthracyclines are widely used chemotherapeutic drugs that can cause progressive and irreversible cardiac damage and fatal heart failure. Several genetic variants associated with anthracycline-induced cardiotoxicity (AIC) have been identified, but they explain only a small proportion of the interindividual differences in AIC susceptibility. Methods In this study, we evaluated the association of low-frequency variants with risk of chronic AIC using the Illumina HumanExome BeadChip array in a discovery cohort of 61 anthracycline-treated breast cancer patients with replication in a second independent cohort of 83 anthracycline-treated pediatric cancer patients, using genebased tests (SKAT-O). Results The most significant associated gene in the discovery cohort was ETFB (electron transfer flavoprotein beta subunit) involved in mitochondrial b-oxidation and ATP production (P = 4.16 9 10 -4 ) and this association was replicated in an independent set of anthracycline-treated cancer patients (P = 2.81 9 10 -3
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Introduction
Anthracyclines are highly effective chemotherapeutic agents used in a wide range of cancers, including hematopoietic and solid tumors. However, a prominent dose-limiting side effect of treatment with anthracyclines is cardiac damage [1] . Anthracycline-induced cardiotoxicity (AIC) may occur during treatment (acute) or can be delayed, being diagnosed within the first year of treatment (early onset) or many years after completion of therapy (late onset) [2] . Both chronic forms are characterized by an irreversible left ventricle (LV) dysfunction that can be progressive and, which, in some cases leads to heart failure and death [3] . In addition to clinical cardiotoxicity, chronic AIC can manifest as asymptomatic cardiotoxicity [4] . The cardiac effects of anthracycline chemotherapy are highly variable between individuals, suggesting a genetic component to AIC susceptibility, apart from well-known risk factors [5] . Several studies have identified genetic variants associated with AIC including genetic polymorphisms in genes involved in anthracycline transport (e.g., ABCB1 [9, 26] , ABCC1 [6, 11, 13, 25] , ABCC2 [6, 15, 28] ) and metabolism (e.g., CBR1 [10] and CBR3 [7, 10, 14, 26] , SLC28A3 [13, 19] ,) or anthracycline-induced oxidative stress (e.g., NCF4 [6, 9, 18] , CYBA [6, 9, 18, 28] ). Because all previous efforts have been focused on the identification of common susceptibility variants (minor allele frequency (MAF) C 5%) and the vast majority [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [23] [24] [25] [26] via a candidate gene approach, it is plausible that analyses of low-frequency (MAF \ 5%) variants could explain additional interpatient variability in susceptibility to AIC. To investigate this hypothesis, we performed a genome-wide association analysis using the Illumina HumanExome Beadchip, which is enriched for low-frequency coding variants ([80% variants with MAF B 1%) [29] , in Spanish breast cancer patients treated with anthracyclines with replication in an independent cohort of anthracyclinetreated pediatric cancer patients.
Materials and methods

Patients
Discovery cohort
Seventy-one patients with pathological confirmed locally advanced breast cancer and treated at the San Carlos University Hospital, (Madrid, Spain) were included. These patients were aged older than 18 years at cancer diagnosis and were enrolled in a neoadjuvant phase II randomized clinical trial [30], as previously described [31] . Patients were randomly assigned to receive four cycles of either neoadjuvant doxorubicin (75 mg/m 2 ) (39 patients) or neoadjuvant docetaxel (100 mg/m 2 ) (32 patients) every 3 weeks. After surgery, patient treatment assignment was crossed-over to receive four cycles of the opposite drug.
Replication cohort
Eighty-three anthracycline-treated patients aged less than 30 years and treated at the La Paz University Hospital or Niñ o Jesús University Hospital in Madrid or at the University Clinic of Navarra in Pamplona were included. Details of the replication cohort have been described elsewhere [32] . All patients were treated with doxorubicin, daunorubicin, or epirubicin as part of their chemotherapy protocol.
Patients in both cohorts received anthracyclines as part of their chemotherapy protocol, had normal cardiac function before anthracycline chemotherapy, and had echocardiographic evaluations (prechemotherapy and postchemotherapy). Patients were excluded if they had a personal history of cardiac disease or were treated with concomitant (neo) adjuvant use of trastuzumab, because of its well-known association with cardiotoxicity. Written informed consent was obtained from adult patients and from the parents or legal guardians of children. The study was approved by the ethics committees of each participating hospital.
Patient medical records were reviewed by oncologists and cardiologists. Demographic, clinical, and therapeutic information extracted from medical records included demographics, disease characteristics, chemotherapy, diagnostic echocardiograms to document baseline and follow-up cardiac function and any cardiac compromise and its severity, and any symptoms or signs consistent with chronic AIC.
AIC definition
AIC in breast cancer patients was defined as early or lateonset (i) cardiac failure grade 3-5 using the Common Terminology Criteria for Adverse Events (CTCAE) 4.0 scoring system (grade 3: severe symptoms at rest or with minimal activity or exertion, intervention indicated; grade 4: life-threatening consequences, urgent intervention indicated; 5: death) [33] and (ii) asymptomatic decrease of left ventricular ejection fraction (LVEF) C10%. Control patients were defined as those having no symptoms or signs of cardiac complications and normal echocardiograms (with a LVEF [60% at both baseline and follow-up and with a decline in LVEF B5%) during and after therapy. Pediatric cases were required to have early/late-onset LV dysfunction evidenced by symptoms/signs of severe mitral valve insufficiency, pericardial effusion, LV hypertrophy, or pulmonary hypertension. The criteria for determining a symptomatic event were established by pediatric cardiologists. Asymptomatic pediatric cases had shortening fraction (SF) B27% any time after anthracycline treatment completion. Pediatric controls had normal echocardiograms (SF C35%) during and after anthracycline therapy.
To rule out acute AIC, only echocardiograms obtained 30 days or more after an anthracycline dose were considered.
Genotyping
To determine the role of low-frequency variants, patients from the discovery cohort were genotyped for the 247,870 variants on the Illumina HumanExome-12v1_A Beadchip (Illumina, San Diego) array according to the manufacturers' recommended protocols. This array includes 247,870 variants, the majority protein-altering, identified from [12,000 exome and genome sequences representing multiple ethnicities and complex traits. Details of variant content and selection strategies are described on the exome array design webpage [29] .
Quality control (QC)
Genotype clustering and calling was carried out using GenTrain version 2.0 in GenomeStudio V2011.1 (Illumina, San Diego,CA) in combination with zCall version 2.2 [34] . Samples were excluded from further analyses if they had more than 5% missing genotype data or showed a level of heterozygosity greater than 4.9 standard deviations from the mean. Variants were excluded if they had a call rate \0.99 or deviated from Hardy-Weinberg equilibrium (P \10 -8 ). A total of 246,060 of 247,870 variants passed QC and 48 451 of those were polymorphic. One case failed heterozygosity and was excluded. The remaining samples were subsequently assessed for population outliers and stratification using a principal component analysis (PCA)-based approach [35] . We carried out two PCAs, the first considering samples in the discovery cohort, to identify population outliers and the second including HapMap samples genotyped using the same array [36] using the snpStats package in R (v.3.0.1). Nine samples in the discovery cohort (2 cases and 7 controls) were excluded as outliers based on inspection of plots of the two first principal components, leaving 61 patients for further analysis (Supplementary Fig. S1 ).
Statistical analyses
We performed statistical analyses using PLINK (v. 1.07) [37, 38] Associations between clinical factors and AIC were assessed in univariable analyses by logistic regression. A P value of \0.05 was considered to be statistically significant.
For gene-based testing, we used the optimized sequence kernel association test (SKAT-O) [39, 40] in GenABEL [41] with default weights [39] . Age at diagnosis was included as covariate in the discovery cohort. Only genes with at least 3 genotyped variants were considered. In total, we tested 4 288 genes of 17,677 covered by at least one variant on the array. Genes with a P \ 5 9 10 -4 in the discovery cohort were assessed in the replication cohort (with available genetic data for the Illumina HumanExome array [32] ), using SKAT-O and including age at diagnosis, cumulative anthracycline dose, and bleomycin concomitant therapy as covariates. While the SKAT-O does not provide any parameter estimates, sensitivity analyses were applied to genes found to be associated, whereby we removed one variant at a time and repeated this SKAT-O test.
The association between variant rs79338777 in ETFB and chronic AIC was tested using logistic regression analysis and considering age at diagnosis as covariate in the discovery cohort, and age at diagnosis, cumulative anthracycline dose, and bleomycin concomitant therapy in the replication cohort. The discovery and replication cohorts were then combined to show the overall significance levels of variant rs79338777, considering age at diagnosis, cumulative anthracycline dose, and whether patients had breast o pediatric tumors as covariates in the logistic regression.
In silico prediction
We used the SIFT algorithm [42] and the programs PolyPhen-2 [43] and MutPred [44] , to predict the impact of rs79338777 on ETFB protein structure or function. SIFT is a sequence homology-based tool to predict tolerated and deleterious substitutions for every position of a given query sequence. PolyPhen-2 classifies variants as ''benign,'' ''possibly damaging,'' or ''probably damaging'' based on a sequence-based characterization of the substitution site, profile analysis of homologous sequences, as well as their location in the three-dimensional structure of the protein molecule. MutPred not only uses multiple alignment information based upon SIFT but also includes information on the gain or loss of 14 different structural and functional properties to assign a pathogenicity score; we considered scores greater than 0.5 to define pathogenicity. In addition, we used PredictSNP [45] to obtain a consensus prediction of pathogenicity based on MAPP, PhD-SNP, PolyPhen-1, Polyphen-2, SIFT, SNAP nsSNPAnalyzer, and PANTHER.
Results
The main patient's demographic and clinical characteristics of the discovery and replication cohorts are shown in Table 1 .
We carried out gene-based analysis to investigate the role of low-frequency variants in chronic AIC using the (SKAT-O) test. The most significantly gene associated with chronic AIC in the discovery cohort was ETFB (electron transfer flavoprotein beta subunit), which encodes a cardiac protein involved in mitochondrial b-oxidation and ATP production [46] (P = 4.16 9 10 -4 ) ( Table 2 ). Given that cardiac mitochondria are preferential targets of anthracycline-mediated cardiotoxicity, we assessed the association of ETFB in an independent cohort of 83 anthracycline-treated pediatric cancer patients and this association was replicated (P = 2.81 9 10 -3 ) ( Table 2) . Examination of variants within ETFB revealed that the low-frequency variant rs79338777 (p.Pro52Leu; c.155C [ T) made the greatest contribution to the ETFB statistical significance (Fig. 1) . The minor T allele of rs79338777 was significantly associated with risk of chronic AIC in both cohorts when analyzed separately (discovery: OR 14.1, P = 0.017, 95% CI 1.60-124; replication: OR 6.17, P = 7.97 9 10 -3 , 95% CI 1.61-27.7), but also when combined (OR 9.00, P = 1.95 9 10 -4 , 95% CI 2.83-28.6) ( Table 3) . Overall, it was found that the T risk allele for rs79338777 to be 3.55 times more frequent in cases than in controls (MAF CASES = 16% v MAF CONTROLS = 5%).
In order to evaluate the impact of the missense variant rs79338777 (p.Pro52Leu) on ETFB protein structure or function, we applied four in silico prediction algorithms. Interestingly, rs79338777 was classified as pathogenic by Positions are based on genome reference consortium human build 37 (GRCh37/hg19). Associations between ETFB and risk of chronic AIC were assessed using SKAT-O considering only genes with at least 3 genotyped variants and including important clinical covariates (discovery cohort: age at diagnosis; replication cohort: age at diagnosis, cumulative anthracycline dose, and bleomycin concomitant therapy) 
Discussion
Genetic variation has been shown to influence susceptibility to AIC; however, the contribution of rare and lowfrequency variants to the interindividual variation in AIC occurrence remains unexplored. Exome chip arrays constitute a cost-effective alternative to whole-exome sequencing and have proven their capacity to identify lowfrequency and rare variants associated with complex diseases [47] [48] [49] [50] . In the present study, we have identified and replicated ETFB as a novel gene associated with chronic AIC susceptibility in anthracycline-treated cancer patients by exome array analysis. ETFB is the b subunit of the heterodimer electron transfer flavoprotein (ETF) protein located in the mitochondrial inner membrane. ETF acts as an electron acceptor of energy production from amino acid and fatty acids that transfers electrons to the main respiratory chain via the ETF ubiquinone oxidoreductase (ETF-QO) and subsequent ATP production [51] . Fatty acids are the main energy substrate of the heart and alterations in mitochondrial fatty acid oxidation occur in different forms of heart disease including heart failure, ischemic heart disease, and diabetic cardiomyopathy [52] . Anthracycline therapy is known to inhibit long-chain fatty acid oxidation and transport across mitochondrial membrane [53] , and mitochondrial dysfunction (decrease ATP production, direct damage to the mitochondria and mitochondria-dependent apoptosis) along with oxidative stress (which interact with each other) has been proposed as major contributors to anthracycline-mediated myocardial injury [54, 55] . Analysis of protein expression in doxorubicin-treated adult rat cardiomyocytes revealed differential downregulation of ETFB [56] . In addition, proteomic analyses of cardiac proteins from mice treated with doxorubicin showed elevated oxidative modifications of cardiac proteins, including ETF-QO, and these oxidative modifications altered their enzymatic activity [57] , thus compromising ATP production in cardiac mitochondria. Taken together, these findings indicate that ETF is an important target in anthracyclinemediated mitochondrial dysfunction. The fact that ETFB was associated to chronic AIC in both breast and pediatric cancer patients points to mitochondrial dysfunction as a molecular mechanism of AIC independent of age at tumor onset. Within ETFB, we found that the variant allele of rs79338777, which has a predicted pathogenic effect according to two of the in silico prediction algorithms used, including the consensus classifier, was significantly associated with higher risk of developing chronic AIC in the combined analysis.
Strengths of this study are that it was based on a wellcharacterized series of uniformly anthracycline-treated patients with extensive patient-, tumor-, and therapy-related information and the notable long-term follow-up of patients, which is critical for a clear distinction between controls and cases of chronic AIC. The main limitation of the present study is the relatively small sample size of individual cohorts.
Although further analysis in larger cohorts of patients and functional characterization of the precise role of the ETFB gene in chronic AIC are required, this study demonstrates that exome array genotyping is a valuable approach to identify novel genes that contribute to chronic AIC susceptibility.
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